Skip to main content
Clinical Trials/NCT06300567
NCT06300567
Not yet recruiting
Not Applicable

Assessment of Patients Not Concluded After Neonatal Screening of Cystic Fibrosis, CFTR-RD Misdiagnosis.

Hôpital Necker-Enfants Malades0 sites400 target enrollmentMay 1, 2024
ConditionsCFTR-RD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
CFTR-RD
Sponsor
Hôpital Necker-Enfants Malades
Enrollment
400
Primary Endpoint
lung Imaging
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Assessment of the outcome of patients not concluded fir cystic fibrosis, either symptomatic patients or asymptomatic children detected by newborn screening for cystic fibrosis. The aim is to identify patients potentially at risk of progressing to the clinical spectrum of cystic fibrosis

Detailed Description

Among patients not concluded for the diagnosis of cystic fibrosis, some are carriers of CFTR-RD mutations, therefore at risk of progressing to a symptomatic form, and may already have a subclinical involvement that it is important to identify. Among patients who do not carry the CFTR-RD genotype, other patients may be at risk of developing symptoms, if they are carriers of an undetected variant or wrongly classified as non-pathogenic. It is important to detect them to prevent the onset of symptoms

Registry
clinicaltrials.gov
Start Date
May 1, 2024
End Date
November 2, 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hôpital Necker-Enfants Malades
Responsible Party
Principal Investigator
Principal Investigator

Isabelle Sermet-Gaudelus

Professor

Hôpital Necker-Enfants Malades

Eligibility Criteria

Inclusion Criteria

  • patients not concluded for the diagnosis of Cystic fibrosis either because of intermediate sweat test or because extensive genetic study has identified 2 vrainats at least 1 being not CF causing

Exclusion Criteria

  • patients carrying 2 CF causing variants of the CFTR gene
  • patients carrying only 1 or no variants of CFTR

Outcomes

Primary Outcomes

lung Imaging

Time Frame: within 3 months after visit

abnormal lung Imaging score, assessing the area of the lung with bronchiectasis, bronchial wall thickening, mucus plug and air trapping

Secondary Outcomes

  • pancreatic function(within 2 weeks after visit)
  • lung infection(within 2 weeks after visit)

Similar Trials